ChromaDex Corporation's (NASDAQ:CDXC) 28% Cheaper Price Remains In Tune With Revenues
Even Though ChromaDex (NASDAQ:CDXC) Has Lost US$73m Market Cap in Last 7 Days, Shareholders Are Still up 389% Over 1 Year
Analysts Offer Insights on Healthcare Companies: Chromadex (CDXC) and Sagimet Biosciences, Inc. Class A (SGMT)
Ladenburg Thalmann Maintains ChromaDex(CDXC.US) With Buy Rating, Raises Target Price to $6.8
Roth MKM Maintains ChromaDex(CDXC.US) With Buy Rating, Maintains Target Price $8
Unwarranted Negative Reaction to ChromaDex 8-K a Buying Opportunity, Says Roth
